The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation

A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry

Sherif Farag, Andrea Bacigalupo, Mary Eapen, Carolyn Hurley, Bo Dupont, Michael A. Caligiuri, Christian Boudreau, Gene Nelson, Machteld Oudshoorn, Jon van Rood, Andrea Velardi, Martin Maiers, Michelle Setterholm, Dennis Confer, Phillip E. Posch, Claudio Anasetti, Naynesh Kamani, Jeffrey S. Miller, Daniel Weisdorf, Stella M. Davies

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Matching for HLA class I alleles, including HLA-C, is an important criterion for outcome of unrelated donor transplantation. However, haplotype-mismatched transplantations for myeloid malignancies, mismatched for killer immunoglobulin-like receptor (KIR) ligands in the graft-versus-host (GVH) direction, is associated with lower rates of graft-versus-host disease (GVHD), relapse, and mortality. This study investigated the effect of KIR ligand mismatching on the outcome of unrelated donor transplantation. The outcomes after 1571 unrelated donor transplantations for myeloid malignancies where donor-recipient pairs were HLA-A, -B, -C, and -DRB1 matched (n = 1004), GVH KIR ligand-mismatched (n = 137), host-versus-graft (HVG) KIR ligand-mismatched (n = 170), and HLA-B and/or -C-mismatched but KIR ligand-matched (n = 260) were compared using Cox regression models. Treatment-related mortality (TRM), treatment failure, and overall mortality were lowest after matched transplantations. Patients who received grafts from donors mismatched at the KIR ligand in the GVH or HVG direction and mismatched at HLA-B and/or C but matched at the KIR ligand had similar rates of TRM, treatment failure, and overall mortality. There were no differences in leukemia recurrence between the 4 groups. These results do not support the choice of an unrelated donor on the basis of KIR ligand mismatch determined from HLA typing.

Original languageEnglish (US)
Pages (from-to)876-884
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume12
Issue number8
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

KIR Receptors
Unrelated Donors
Registries
Transplantation
Bone Marrow
Ligands
Transplants
Research
HLA-B Antigens
Mortality
HLA-C Antigens
Treatment Failure
Tissue Donors
Recurrence
Histocompatibility Testing
HLA-A Antigens
Graft vs Host Disease
Proportional Hazards Models
Haplotypes
Neoplasms

Keywords

  • Bone marrow transplantation
  • KIR ligand incompatibility
  • Leukemia
  • Unrelated donor

ASJC Scopus subject areas

  • Transplantation

Cite this

The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation : A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. / Farag, Sherif; Bacigalupo, Andrea; Eapen, Mary; Hurley, Carolyn; Dupont, Bo; Caligiuri, Michael A.; Boudreau, Christian; Nelson, Gene; Oudshoorn, Machteld; van Rood, Jon; Velardi, Andrea; Maiers, Martin; Setterholm, Michelle; Confer, Dennis; Posch, Phillip E.; Anasetti, Claudio; Kamani, Naynesh; Miller, Jeffrey S.; Weisdorf, Daniel; Davies, Stella M.

In: Biology of Blood and Marrow Transplantation, Vol. 12, No. 8, 08.2006, p. 876-884.

Research output: Contribution to journalArticle

Farag, S, Bacigalupo, A, Eapen, M, Hurley, C, Dupont, B, Caligiuri, MA, Boudreau, C, Nelson, G, Oudshoorn, M, van Rood, J, Velardi, A, Maiers, M, Setterholm, M, Confer, D, Posch, PE, Anasetti, C, Kamani, N, Miller, JS, Weisdorf, D & Davies, SM 2006, 'The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry', Biology of Blood and Marrow Transplantation, vol. 12, no. 8, pp. 876-884. https://doi.org/10.1016/j.bbmt.2006.05.007
Farag, Sherif ; Bacigalupo, Andrea ; Eapen, Mary ; Hurley, Carolyn ; Dupont, Bo ; Caligiuri, Michael A. ; Boudreau, Christian ; Nelson, Gene ; Oudshoorn, Machteld ; van Rood, Jon ; Velardi, Andrea ; Maiers, Martin ; Setterholm, Michelle ; Confer, Dennis ; Posch, Phillip E. ; Anasetti, Claudio ; Kamani, Naynesh ; Miller, Jeffrey S. ; Weisdorf, Daniel ; Davies, Stella M. / The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation : A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. In: Biology of Blood and Marrow Transplantation. 2006 ; Vol. 12, No. 8. pp. 876-884.
@article{6fc7c285c1614a1a89f42b132227e7c2,
title = "The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry",
abstract = "Matching for HLA class I alleles, including HLA-C, is an important criterion for outcome of unrelated donor transplantation. However, haplotype-mismatched transplantations for myeloid malignancies, mismatched for killer immunoglobulin-like receptor (KIR) ligands in the graft-versus-host (GVH) direction, is associated with lower rates of graft-versus-host disease (GVHD), relapse, and mortality. This study investigated the effect of KIR ligand mismatching on the outcome of unrelated donor transplantation. The outcomes after 1571 unrelated donor transplantations for myeloid malignancies where donor-recipient pairs were HLA-A, -B, -C, and -DRB1 matched (n = 1004), GVH KIR ligand-mismatched (n = 137), host-versus-graft (HVG) KIR ligand-mismatched (n = 170), and HLA-B and/or -C-mismatched but KIR ligand-matched (n = 260) were compared using Cox regression models. Treatment-related mortality (TRM), treatment failure, and overall mortality were lowest after matched transplantations. Patients who received grafts from donors mismatched at the KIR ligand in the GVH or HVG direction and mismatched at HLA-B and/or C but matched at the KIR ligand had similar rates of TRM, treatment failure, and overall mortality. There were no differences in leukemia recurrence between the 4 groups. These results do not support the choice of an unrelated donor on the basis of KIR ligand mismatch determined from HLA typing.",
keywords = "Bone marrow transplantation, KIR ligand incompatibility, Leukemia, Unrelated donor",
author = "Sherif Farag and Andrea Bacigalupo and Mary Eapen and Carolyn Hurley and Bo Dupont and Caligiuri, {Michael A.} and Christian Boudreau and Gene Nelson and Machteld Oudshoorn and {van Rood}, Jon and Andrea Velardi and Martin Maiers and Michelle Setterholm and Dennis Confer and Posch, {Phillip E.} and Claudio Anasetti and Naynesh Kamani and Miller, {Jeffrey S.} and Daniel Weisdorf and Davies, {Stella M.}",
year = "2006",
month = "8",
doi = "10.1016/j.bbmt.2006.05.007",
language = "English (US)",
volume = "12",
pages = "876--884",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation

T2 - A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry

AU - Farag, Sherif

AU - Bacigalupo, Andrea

AU - Eapen, Mary

AU - Hurley, Carolyn

AU - Dupont, Bo

AU - Caligiuri, Michael A.

AU - Boudreau, Christian

AU - Nelson, Gene

AU - Oudshoorn, Machteld

AU - van Rood, Jon

AU - Velardi, Andrea

AU - Maiers, Martin

AU - Setterholm, Michelle

AU - Confer, Dennis

AU - Posch, Phillip E.

AU - Anasetti, Claudio

AU - Kamani, Naynesh

AU - Miller, Jeffrey S.

AU - Weisdorf, Daniel

AU - Davies, Stella M.

PY - 2006/8

Y1 - 2006/8

N2 - Matching for HLA class I alleles, including HLA-C, is an important criterion for outcome of unrelated donor transplantation. However, haplotype-mismatched transplantations for myeloid malignancies, mismatched for killer immunoglobulin-like receptor (KIR) ligands in the graft-versus-host (GVH) direction, is associated with lower rates of graft-versus-host disease (GVHD), relapse, and mortality. This study investigated the effect of KIR ligand mismatching on the outcome of unrelated donor transplantation. The outcomes after 1571 unrelated donor transplantations for myeloid malignancies where donor-recipient pairs were HLA-A, -B, -C, and -DRB1 matched (n = 1004), GVH KIR ligand-mismatched (n = 137), host-versus-graft (HVG) KIR ligand-mismatched (n = 170), and HLA-B and/or -C-mismatched but KIR ligand-matched (n = 260) were compared using Cox regression models. Treatment-related mortality (TRM), treatment failure, and overall mortality were lowest after matched transplantations. Patients who received grafts from donors mismatched at the KIR ligand in the GVH or HVG direction and mismatched at HLA-B and/or C but matched at the KIR ligand had similar rates of TRM, treatment failure, and overall mortality. There were no differences in leukemia recurrence between the 4 groups. These results do not support the choice of an unrelated donor on the basis of KIR ligand mismatch determined from HLA typing.

AB - Matching for HLA class I alleles, including HLA-C, is an important criterion for outcome of unrelated donor transplantation. However, haplotype-mismatched transplantations for myeloid malignancies, mismatched for killer immunoglobulin-like receptor (KIR) ligands in the graft-versus-host (GVH) direction, is associated with lower rates of graft-versus-host disease (GVHD), relapse, and mortality. This study investigated the effect of KIR ligand mismatching on the outcome of unrelated donor transplantation. The outcomes after 1571 unrelated donor transplantations for myeloid malignancies where donor-recipient pairs were HLA-A, -B, -C, and -DRB1 matched (n = 1004), GVH KIR ligand-mismatched (n = 137), host-versus-graft (HVG) KIR ligand-mismatched (n = 170), and HLA-B and/or -C-mismatched but KIR ligand-matched (n = 260) were compared using Cox regression models. Treatment-related mortality (TRM), treatment failure, and overall mortality were lowest after matched transplantations. Patients who received grafts from donors mismatched at the KIR ligand in the GVH or HVG direction and mismatched at HLA-B and/or C but matched at the KIR ligand had similar rates of TRM, treatment failure, and overall mortality. There were no differences in leukemia recurrence between the 4 groups. These results do not support the choice of an unrelated donor on the basis of KIR ligand mismatch determined from HLA typing.

KW - Bone marrow transplantation

KW - KIR ligand incompatibility

KW - Leukemia

KW - Unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=33746096999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746096999&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2006.05.007

DO - 10.1016/j.bbmt.2006.05.007

M3 - Article

VL - 12

SP - 876

EP - 884

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -